

FILE 'HOME' ENTERED AT 12:55:06 ON 07 JUL 2006

=> index bioscience medicine

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.63	0.63

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 12:56:55 ON 07 JUL 2006

71 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s (recombinant or engineer?2 or mutated or mutagen?) (A) serum albumin (P) (cosmetic or (skin or hair) (A) (cleanser? or cream or lotion or shampoo))
0* FILE ADISCTI

=> s ((recombinant or engineer? or mutat? or mutagen?) (A) serum albumin) (P) (cosmetic or (skin or hair) (A) (cleanser? or cream or lotion or shampoo))
0* FILE ADISNEWS
0* FILE ANTE
0* FILE AQUALINE
0* FILE BIOENG
2* FILE BIOTECHABS
2* FILE BIOTECHDS
0* FILE BIOTECHNO

13 FILES SEARCHED...

1 FILE CAPLUS
0* FILE CEABA-VTB
0* FILE CIN

23 FILES SEARCHED...

0* FILE ES BIOBASE
0* FILE FOMAD
0* FILE FOREGE
0* FILE FROSTI
0* FILE FSTA
2 FILE IFIPAT

39 FILES SEARCHED...

0* FILE KOSMET
0* FILE NTIS
0* FILE NUTRACEUT
0* FILE PASCAL
0* FILE PHARMAML

56 FILES SEARCHED...

1 FILE TOXCENTER
2 FILE USPATFULL
0* FILE WATER
1 FILE WPIDS
1 FILE WPINDEX

68 FILES SEARCHED...

8 FILES HAVE ONE OR MORE ANSWERS, 71 FILES SEARCHED IN STNINDEX

L1 QUE ((RECOMBINANT OR ENGINEER? OR MUTAT? OR MUTAGEN?) (A) SERUM ALBUMIN) (P) (COSMETIC OR (SKIN OR HAIR) (A) (CLEANSER? OR CREAM OR LOTION OR SHAMPOO))

=> D rank

F1 2 IFIPAT

F2 2 USPATFULL
 F3 2* BIOTECHABS
 F4 2* BIOTECHDS
 F5 1 CAPLUS
 F6 1 TOXCENTER
 F7 1 WPIDS
 F8 1 WPINDEX

=> file F1 F3-8

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.49	6.12

FILE 'IFIPAT' ENTERED AT 13:02:21 ON 07 JUL 2006
 COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 13:02:21 ON 07 JUL 2006
 COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'CAPLUS' ENTERED AT 13:02:21 ON 07 JUL 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 13:02:21 ON 07 JUL 2006
 COPYRIGHT (C) 2006 ACS

FILE 'WPIDS' ENTERED AT 13:02:21 ON 07 JUL 2006
 COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S l1

L2 2 FILE IFIPAT
 PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
 FIELD CODE - 'AND' OPERATOR ASSUMED 'ALBUMIN) (P) '
 L3 2 FILE BIOTECHDS
 L4 1 FILE CAPLUS
 L5 1 FILE TOXCENTER
 L6 1 FILE WPIDS

TOTAL FOR ALL FILES
 L7 7 L1

=> dup rem l7

PROCESSING COMPLETED FOR L7
 L8 4 DUP REM L7 (3 DUPLICATES REMOVED)

=> d l8 1-4 ibib abs

L8 ANSWER 1 OF 4 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
 ACCESSION NUMBER: 2006-05372 BIOTECHDS
 TITLE: Novel isolated mammalian serum albumin, preferably human
 having amino acid lacking reactive sulfhydryl/methionine
 substituted for cysteine at specific positions or equivalent
 to specific positions, useful as blood volume expander;
 mammal recombinant serum
 albumin production by expression in transgenic
 plant for blood volume expander
 AUTHOR: CARTER D C
 PATENT ASSIGNEE: CARTER D C

PATENT INFO: US 2006018859 26 Jan 2006
APPLICATION INFO: US 2005-183163 18 Jul 2005
PRIORITY INFO: US 2005-183163 18 Jul 2005; US 2004-588371 16 Jul 2004
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 2006-109150 [11]
AN 2006-05372 BIOTECHDS
AB DERWENT ABSTRACT:

NOVELTY - An isolated mammalian serum albumin (I), preferably human serum albumin having an amino acid lacking a reactive sulfhydryl or methionine substituted for cysteine at position 34 of the amino acid sequence, or at the position equivalent to position 34 of the human serum albumin amino acid sequence, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) a pharmaceutical or cosmetic composition comprising (I), and vehicle, carrier or excipient; (2) an isolated nucleic acid molecule encoding the amino acid sequence of (I) or its degenerates; and (3) reducing (M1) the affinity of mammalian serum albumin, preferably human serum albumin to chemical or biological molecules, which bind to a sulfhydryl group, involves: (a) replacing cysteine at position 34 of the human serum albumin amino acid sequence with an amino acid lacking a sulfhydryl; or (b) substituting an amino acid lacking a sulfhydryl group for the cysteine at the position equivalent to position 34 of the human serum albumin amino acid sequence.

BIOTECHNOLOGY - Preparation: (I) is prepared by recombinant DNA technique. Preferred Albumin: In (I), the amino acid substituting for the cysteine at position 34 is chosen from methionine, alanine, valine, serine, threonine, leucine, isoleucine, glycine, phenylalanine, tyrosine, aspartic acid, glutamic acid, glutamine, asparagine and lysine. The substitution is achieved through recombinant unit, or physical or chemical unit. (I) is produced using transgenic plant. Preferred Method: In (M1), the chemical or biological molecule is a trace metal.

USE - (I) is useful as a blood volume expander, and for reducing a wide variety of undesired chemical reactions with small molecules, biologics, and metal elements such as gold, mercury, silver, nickel or copper. (I) is useful in blood products such as blood volume expander and blood substitutes to cosmetics and other topical applications.

(I) is useful in medical applications, and scientific applications involving analytical spectroscopy. (I) is useful for increasing blood volume and transporting oxygen in patient's circulatory system that have suffered from severe loss of blood or during surgical operations.

ADVANTAGE - (I) is highly safe and effective in a variety of applications such as blood product, cosmetic, medicament or an additive, and causes less allergic reactions in the human being, with improved clarity and homogeneity.

EXAMPLE - None given.(6 pages)

L8 ANSWER 2 OF 4 IFIPAT COPYRIGHT 2006 IFI on STN DUPLICATE 1
AN 10530636 IFIPAT;IFIUDB;IFICDB
TITLE: COMPOSITION FOR THERAPEUTIC AND COSMETIC
BOTULINUM TOXIN; BOTULINUM NEUROTOXIN FORMULATED WITH
A RECOMBINANT SERUM
ALBUMIN
INVENTOR(S): Borodic; Gary, Canton, MA, US
PATENT ASSIGNEE(S): Unassigned
PATENT ASSIGNEE PROBABLE: Botulinum Toxin Research Associates Inc (Probable)
AGENT: Milbank, Tweed, Hadley & McCloy, LLP, One Chase
Manhattan Plaza, New York, NY, 10005, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2004037853	A1	20040226
APPLICATION INFORMATION:	US 2003-446562		20030528

	NUMBER	DATE
PRIORITY APPLN. INFO.:	US 2002-383570P	20020528 (Provisional)
FAMILY INFORMATION:	US 2004037853	20040226
DOCUMENT TYPE:	Utility Patent Application - First Publication	
FILE SEGMENT:	CHEMICAL APPLICATION	
OTHER SOURCE:	CA 140:216156	

PARENT CASE DATA:

I claim priority to U.S. Provisional Patent Application Serial No. 60/383,570, filed May 28, 2002, and hereby incorporate said application by reference herein in its entirety.

NUMBER OF CLAIMS: 16

AB This invention relates to a composition of botulinum based pharmaceuticals used for therapeutic and cosmetic treatment. This invention offers an improvement on the prior art by eliminating the potential of blood-borne contamination with botulinum based pharmaceuticals. Recombinant serum albumin is taught for use in the place of human serum albumin as a stabilizing or enhancing agent.

CLMN 16

L8 ANSWER 3 OF 4 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN

ACCESSION NUMBER: 2004-06830 BIOTECHDS

TITLE: Preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in a plant comprises transforming plant cells with a polynucleotide sequence that encodes the fusion polypeptide; vector-mediated fusion gene transfer and expression in transgenic plant for recombinant protein production and disease therapy

AUTHOR: LEE S; YOO J; PARK S

PATENT ASSIGNEE: NEXGEN BIOTECHNOLOGIES INC

PATENT INFO: WO 2004005520 15 Jan 2004

APPLICATION INFO: WO 2003-KR1310 2 Jul 2003

PRIORITY INFO: KR 2002-38165 3 Jul 2002; KR 2002-38165 3 Jul 2002

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: WPI: 2004-091372 [09]

AN 2004-06830 BIOTECHDS

AB DERWENT ABSTRACT:

NOVELTY - Preparing a fusion polypeptide comprising epidermal growth factor (EGF) and human serum albumin in a plant comprising transforming plant cells with a polynucleotide sequence comprising a sequence that encodes the fusion polypeptide, a promoter, and a 3'-non-translated region, is new.

DETAILED DESCRIPTION - Preparing a fusion polypeptide comprising epidermal growth factor (EGF) and human serum albumin in a plant comprising transforming plant cells with a polynucleotide sequence comprising a sequence that encodes the fusion polypeptide, a promoter, and a 3'-non-translated region, comprising: (a) transforming plant cells with a polynucleotide sequence comprising a nucleotide sequence encoding the fusion polypeptide comprising EGF and human serum albumin linked to the C-terminal or N-terminal of the EGF, where the stability of the EGF is enhanced by virtue of the human serum albumin; a promoter that functions in plant cells to cause the production of an RNA molecule operably linked to the nucleotide sequence; and a 3'-non-translated region that functions in plant cells to cause the polyadenylation of the 3'-end of the RNA molecule; (b) selecting transformed plant cells; (c) regenerating a plant from the transformed cells; and (d) recovering the

fusion polypeptide from the regenerated plant.

WIDER DISCLOSURE - The following are also disclosed as new: (1) a nucleotide sequence encoding the fusion polypeptide; (2) an expression vector comprising the nucleotide sequence; (3) a cosmetic composition for skin care; and (4) a pharmaceutical composition.

BIOTECHNOLOGY - Preferred Plant: In preparing a fusion polypeptide, the plant is *Nicotiana tabacum*, *Cucumis melo*, *Cucumis sativa*, *Citrullus vulgaris*, or *Brassica campestris*. Preferred Nucleic Acid: The nucleotide sequence of the EGF comprises nucleotide 1-159 of a sequence of 165 amino acids fully defined in the specification. Preferred Fusion Protein: The human serum albumin is linked to the C-terminal of the EGF. Preferred Method: The method alternatively comprises: (a) inoculating an explant material from the plant with *Agrobacterium tumefaciens* harboring a vector that is capable of inserting into a genome of cell from the plant and containing the nucleotide sequence cited above; (b) regenerating the inoculated explant material on a regeneration medium to obtain regenerated shoots; (c) culturing the regenerated shoots on a rooting medium to obtain a transformed plant, where the transformed plant is capable of expressing the nucleotide sequence; and (d) recovering the fusion polypeptide from the transformed plant.

ACTIVITY - Gastrointestinal-Gen.; Antiulcer; Antiparkinsonian; Dermatological; Vulnerary. No biological data given.

MECHANISM OF ACTION - Protein Therapy. No biological data given.

USE - The method is useful for preparing a fusion polypeptide comprising epidermal growth factor and human serum albumin in plant (claimed). The fusion polypeptide is useful for preparing a cosmetic composition for skin care, and a pharmaceutical composition for treating, e.g. gastric ulcers, neurodegenerative disorders such as Parkinson's disease and wound healing.

ADMINISTRATION - Dosage is 0.001-100 mg/kg. Administration is oral, parenteral or topical.

EXAMPLE - *Escherichia coli* BL21 (DE3) transformed with Albumin-EGF/pET28alpha was cultured to OD650 0.5 in 5 liter fermenter and the expression of the fused gene was then induced by addition of 0.5 mM IPTG. Following additional culture for 5-6 hours, the cells were collected by centrifugation. The collected cells were completely suspended in 40 ml of buffer, disrupted by ultrasonification, centrifuged and the resulting supernatant was then collected. The supernatant was electrophoresed pm 8 % polyacrylamide gel to verify the expression of the fusion protein. The supernatant was applied to Ni-agarose column activated with a binding buffer and passed at a rate of 1-3 ml/minute. Then, using the binding buffer, the column was washed and each of 20, 40, 60, 100, 300 and 500 nM imidazole solutions was applied to the column in stepwise manner, finally eluting the fusion protein. (57 pages)

L8 ANSWER 4 OF 4 IFIPAT COPYRIGHT 2006 IFI on STN
AN 10063370 IFIPAT;IFIUDB;IFICDB
TITLE: SERUM ALBUMIN COMPOSITIONS FOR USE IN CLEANSING OR
DERMATOLOGICAL PRODUCTS FOR SKIN OR HAIR;
HYPOALLERGENS
INVENTOR(S): Carter; Daniel C., Madison, AL, US
PATENT ASSIGNEE(S): Unassigned
PATENT ASSIGNEE PROBABLE: New Century Pharmaceuticals Inc (Probable)
AGENT: LARSON & TAYLOR, PLC, 1199 NORTH FAIRFAX STREET,
SUITE 900, ALEXANDRIA, VA, 22314, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2002006892	A1	20020117
APPLICATION INFORMATION:	US 2000-740821		20001221

APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
-----	-----	-----

CONTINUATION-IN-PART OF: US 2000-616962 20000714 PENDING
FAMILY INFORMATION: US 2002006892 20020117
DOCUMENT TYPE: Utility
Patent Application - First Publication
FILE SEGMENT: CHEMICAL
APPLICATION
OTHER SOURCE: CA 136:111285

NUMBER OF CLAIMS: 20

AB A hypoallergenic cleansing, cosmetic, conditioning or dermatological composition for treating skin or hair is provided which contains serum albumin in an amount effective to achieve cleansing, conditioning, wound debriment, or other beneficial cosmetic or dermatological purpose for skin or hair, along with a suitable cleansing, conditioning, cosmetic, antibacterial or dermatological agent, vehicle, carrier or excipient. The compositions may be in any suitable form for treating skin or hair, such as a soap, shampoo, cream, oil, lotion, gel, gel-based ointment, and the like. The serum albumin compositions are preferably prepared using human serum albumin produced by recombinant means, and such compositions are useful in that they allow the albumin to be absorbed in the surface of skin or hair so as to replenish the structure of these tissues when utilized as a cleansing, cosmetic or dermatological agent. The compositions of the present invention will provide cleansing, cosmetic or dermatological compositions that can be used safely and effectively with reduced likelihood of allergic reaction.

CLMN 20

=>

=> s ((recombinant or engineer? or mutat? or mutagen?) (A) serum albumin) and
(cosmetic or (skin or hair) (A) (cleanser? or cream or lotion or shampoo))

L9 2 FILE IFIPAT
L10 2 FILE BIOTECHDS
L11 1 FILE CAPLUS
L12 1 FILE TOXCENTER
L13 1 FILE WPIDS

TOTAL FOR ALL FILES

L14 7 ((RECOMBINANT OR ENGINEER? OR MUTAT? OR MUTAGEN?) (A) SERUM
 ALBUMIN) AND (COSMETIC OR (SKIN OR HAIR) (A) (CLEANSER? OR CREAM
 OR LOTION OR SHAMPOO))

=> dup rem L14

PROCESSING COMPLETED FOR L14

L15 4 DUP REM L14 (3 DUPLICATES REMOVED)

WEST Search History

DATE: Friday, July 07, 2006

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT,USOC; THES=ASSIGNEE; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L6	(recombinant\$ engineer\$ matat\$ mutagenesis) with serum albumin same (cosmetic\$ (skin hair))	13
<input type="checkbox"/>	L5	(recombinant\$ engineer\$ matat\$ mutagenesis) with serum albumin same (cosmetic\$ (skin hair) with cleanser)	5
<input type="checkbox"/>	L4	(recombinant\$ engineer\$ matat\$ mutagenesis) with serum albumin and (cosmetic\$ (skin hair) with cleanser)	292
<input type="checkbox"/>	L3	(recombinant\$ engineer\$ matat\$ mutagenesis) with serum albumin and (cosmetic\$ (skin hair) near3 (cleanser\$ cream lotion shampoo))	319
<input type="checkbox"/>	L2	(recombinant\$ engineer\$ matat\$ mutagenesis) same serum albumin same (cosmetic\$ (skin hair) near3 (cleanser\$ cream lotion shampoo))	5
<input type="checkbox"/>	L1	(recombinant\$ engineer\$ matat\$ mutagenesis) same serum albumin and (cosmetic\$ (skin hair) near3 (cleanser\$ cream lotion shampoo))	715

END OF SEARCH HISTORY